TrialArthritis & rheumatology (Hoboken, N.J.)2026

Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis.

Jinqi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.